Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study

Abstract Endoscopic sleeve gastroplasty (ESG) and semaglutide are established therapies for obesity. However, comparative real-world data remain limited. We compared the effectiveness and safety of ESG versus oral semaglutide 14 mg in adults with obesity. In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18–65 years with body mass index (BMI) ≥30, or ≥27 kg/m2 with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months’ follow-up were included. Primary endpoint was percentage total body weight loss (%TBWL) at 6 months. Secondary outcomes included treatment responder rates, adverse events, and 12-month weight outcomes. Analyses included Welch’s two-sample t-tests, analysis of covariance adjusted for age, sex, baseline BMI, and diabetes, inverse probability of treatment weighting (IPTW), and 1:1 propensity score matching. 150 patients were included (ESG n=50; semaglutide n=100). Baseline characteristics were broadly similar between groups. At 6 months, mean %TBWL was significantly higher with ESG than semaglutide (12.72±5.67% vs 8.67±3.84%, P=0.0001) that remained after covariate adjustment (adjusted mean difference 4.04%, P=0.0001), IPTW analysis (P